Výsledky vyhledávání

Akademický článek

Evaluation of treatment patterns, healthcare resource utilization and cost of illness for sickle cell disease in Ghana: a private medical insurance claims database study

Autor: Kwaku Marfo, Yvonne Dei-Adomakoh, Catherine Segbefia, Duah Dwomoh, Adeline Edgal, Nancy Ampah, Badarinath Chickballapur Ramachandrachar, Kumaresan Subramanyam, Ashok Natarajan, Olufolake Egbujo, Kenneth I. Ataga

Publikováno v: BMC Health Services Research, Vol 23, Iss 1, Pp 1-14 (2023)

Abstract Background Sickle cell disease (SCD) is a major public health concern in sub-Saharan Africa, accounting for nearly 75% of the global disease burden. The current analysis evaluated patient characteristics, treatment patterns, healthcare resou

Externí odkaz: https://doaj.org/article/e6c59267870f4939bf453c91a2c5a4c2

Zobrazit plný text záznamu

Plný text ve formátu HTML

Akademický článek

Barriers and facilitators to community acceptability of integrating point-of-care testing to screen for sickle cell disease in children in primary healthcare settings in rural Upper East Region of Northern Ghana.

Autor: Samuel T Chatio, Enyonam Duah, Lucy O Ababio, Nicola Lister, Olufolake Egbujo, Kwaku Marfo, Raymond Aborigo, Patrick Ansah, Isaac Odame

Publikováno v: PLoS ONE, Vol 19, Iss 5, p e0303520 (2024)

IntroductionSickle cell disease (SCD) remains a public health problem especially in sub-Saharan Africa including Ghana. While pilot initiatives in Africa have demonstrated that neonatal screening coupled with early intervention reduces SCD-related mo

Externí odkaz: https://doaj.org/article/44a6ebacd82f4749853b60efe5e29426

Zobrazit plný text záznamu

Plný text ve formátu HTML

Akademický článek

Bridging the Access Gap for Comprehensive Sickle Cell Disease Management Across Sub-Saharan Africa: Learnings for Other Global Health Interventions?

Autor: Lutz Hegemann, Vas Narasimhan, Kwaku Marfo, Patrick Kuma-Aboagye, Solomon Ofori-Acquah, Isaac Odame

Publikováno v: Annals of Global Health, Vol 89, Iss 1, Pp 76-76 (2023)

Background: Sickle cell disease (SCD) is a major unresolved global health issue, with the highest disease burden in sub-Saharan African countries; yet, SCD care has not proportionally reached patients in these regions, and the disease has received li

Externí odkaz: https://doaj.org/article/6c6086d834ce496c8cf242c31d12a5eb

Zobrazit plný text záznamu

Akademický článek

Long-term Safety of Secukinumab Over Five Years in Patients with Moderate-to-severe Plaque Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Update on Integrated Pooled Clinical Trial and Post-marketing Surveillance Data

Autor: Alice B. Gottlieb, Atul Deodhar, Iain B. Mcinnes, Xenofon Baraliakos, Kristian Reich, Stefan Schreiber, Weibin Bao, Kwaku Marfo, Hanno B. Richards, Luminita Pricop, Abhijit Shete, Vivek Trivedi, Deborah Keefe, Charis C. Papavassilis, Piotr Jagiello, Philemon Papanastasiou, Philip J. Mease, Mark Lebwohl

Publikováno v: Acta Dermato-Venereologica, Vol 102 (2022)

Secukinumab, a selective interleukin (IL)-17A inhibitor, is approved for use in adult and paediatric psoriasis, psoriatic arthritis, ankylosing spondylitis and non-radiographic axial spondyloarthritis. The aim of this study was to report the long-ter

Externí odkaz: https://doaj.org/article/df7f9d86b24a460b8b32d03dd5d1cb7c

Zobrazit plný text záznamu

Akademický článek

Tacrolimus Pharmacokinetic and Pharmacogenomic Differences between Adults and Pediatric Solid Organ Transplant Recipients

Autor: Amy Lu, Jerry Altshuler, Kwaku Marfo

Publikováno v: Pharmaceutics, Vol 2, Iss 3, Pp 291-299 (2010)

Tacrolimus is a calcineurin inhibitor immunosuppressant that has seen considerable use in both adult and pediatric solid organ transplant recipients. Though there is much pharmacokinetic data available for tacrolimus in the adult population, the lite

Externí odkaz: https://doaj.org/article/bf5a5967d2304dd88891e9a592107c6b

Zobrazit plný text záznamu

Clinical efficacy and safety of secukinumab in patients with psoriasis and comorbidities: pooled analysis of 4 phase 3 clinical trials

Autor: Alice B. Gottlieb, Christopher E.M. Griffiths, Jennifer Frueh, Kwaku Marfo, Jashin J. Wu, Elisa Muscianisi, Xiangyi Meng, Mark Lebwohl

Publikováno v: Journal of Dermatological Treatment. 33:1482-1490

The influence of comorbidities on the efficacy and safety of biologic therapies in psoriasis has not been rigorously explored.To assess the incremental burden of comorbidities on clinical efficacy and safety of secukinumab vs. etanercept and placebo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d8d9162b5eadd25290996ae671967d5a
https://doi.org/10.1080/09546634.2020.1832187

Zobrazit plný text záznamu

Association of Secukinumab Treatment With Tuberculosis Reactivation in Patients With Psoriasis, Psoriatic Arthritis, or Ankylosing Spondylitis

Autor: John W. Baddley, Marina Magrey, Jennifer Soung, Kwaku Marfo, Boni E. Elewski, Abhishek Sharma, Manmath Patekar, Weibin Bao, Dorothy L. Keininger, Enrique R. Soriano, Atul Deodhar, Abhijit Shete, Mark Lebwohl, Phoebe Rich

Publikováno v: JAMA Dermatol

Importance Approximately one-quarter of the global population have latent tuberculosis infection (LTBI), and tuberculosis (TB) is accountable for more than 1.5 million deaths annually. Methotrexate, cyclosporine, and tumor necrosis factor inhibitors

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9b9b94ddb594681243b77de3af11218c
https://doi.org/10.1001/jamadermatol.2020.3257

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání